文献速递眼底病与葡萄膜炎

Abicipar-Pegol的功能表征:一种高效抑制血管生成与血管通透性的抗VEGF DARPin治疗药物

Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

本文通过体外和体内实验表征了靶向VEGF-A的DARPin分子Abicipar-pegol的药效学特性。Abicipar对可溶性VEGF-A亚型具有高亲和力,在人VEGF-A165上的结合亲和力约为兰尼单抗和贝伐单抗的100倍;在角膜新生血管小鼠模型和慢性视网膜新生血管兔模型中有效阻断新生血管和血管通透性;在兔VEGF-A165诱导的视网膜血管病变模型中,等摩尔剂量下作用持续时间长于兰尼单抗。

要点

  • Abicipar对人VEGF-A165的亲和力约为兰尼单抗和贝伐单抗的100倍。
  • Abicipar在角膜新生血管小鼠模型和慢性新生血管兔模型中有效阻断新生血管和血管通透性。
  • 兔VEGF-A165诱导血管病变模型中,等摩尔剂量下Abicipar作用持续时间长于兰尼单抗。

核心结论

  • Abicipar对可溶性VEGF-A亚型具有高亲和力,并在体外和体内模型中有效抑制血管生成和血管通透性。
  • 这些数据支持将Abicipar用于以新生血管和血管渗漏为特征的眼部疾病的治疗测试。

研究设计与样本

  • 采用动力学排斥分析(KinExA)评估Abicipar的结合亲和力。
  • 体外实验评估Abicipar对人脐静脉内皮细胞中VEGF-A165诱导的钙动员和管腔形成的影响。
  • 体内实验使用小鼠角膜新生血管模型和兔慢性视网膜新生血管模型。
  • 在兔VEGF-A165诱导的视网膜血管病变模型中比较Abicipar与兰尼单抗的疗效。

主要发现

  • Abicipar对人VEGF-A165的结合亲和力约为兰尼单抗和贝伐单抗的100倍。
  • Abicipar对大鼠VEGF-A164的亲和力与人VEGF-A165相似,但对兔VEGF-A165的亲和力约低20倍。
  • Abicipar在细胞实验和体内血管生成及血管渗漏模型中有效。
  • Abicipar在小鼠角膜新生血管模型中阻断新生血管,在兔慢性新生血管模型中阻断血管通透性。
  • 在兔VEGF-A165诱导的血管病变模型中,等摩尔剂量下Abicipar的作用持续时间长于兰尼单抗。

关键数值与推荐

  • Abicipar对人VEGF-A165的结合亲和力约为兰尼单抗和贝伐单抗的100倍。
  • Abicipar对兔VEGF-A165的亲和力比对人类VEGF-A165约低20倍。

临床怎么用

  • Abicipar的高亲和力和较长作用持续时间支持其作为视网膜新生血管和血管渗漏疾病的潜在治疗选择。
  • 临床应用中需注意不同物种间VEGF-A亲和力的差异,兔模型数据外推至人时需谨慎。

局限性

  • 研究主要基于动物模型和体外实验,尚未提供人体临床试验的有效性和安全性数据。
  • Abicipar对兔VEGF-A165的亲和力比对人VEGF-A165低约20倍,可能影响兔模型结果向人类的转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: DARPin molecules are a novel class of small proteins that contain engineered ankyrin repeat domain(s) and bind to target proteins with high specificity and affinity. Abicipar-pegol (abicipar), a DARPin molecule targeting vascular endothelial growth factor-A (VEGF-A), is currently under evaluation in patients with age-related macular degeneration. The pharmacodynamic properties of abicipar were characterized using in vivo and in vitro assays. METHODS: The binding affinity of abicipar was assessed using a kinetic exclusion assay (KinExA). In vitro assays evaluated abicipar effects on VEGF-A165-induced calcium mobilization and tube formation in human umbilical vein endothelial cells. Abicipar was tested in vivo in a mouse model of corneal neovascularization and a rabbit model of chronic retinal neovascularization. The efficacies of abicipar and ranibizumab were compared in a rabbit model of VEGF-A165-induced retinal vasculopathy. RESULTS: Abicipar has a high affinity for the soluble isoforms of VEGF-A; binding affinities for human VEGF-A165 are approximately 100-fold greater than those of ranibizumab and bevacizumab and are similar for rat VEGF-A164 but approximately 20-fold lower for rabbit VEGF-A165. Abicipar was effective in cell-based and in vivo models of angiogenesis and vascular leak, blocking neovascularization in a mouse model of corneal neovascularization and vascular permeability in a rabbit model of chronic neovascularization. In a rabbit model of VEGF-A165-induced vasculopathy, the duration of effect of abicipar was longer than ranibizumab when the two compounds were administered at molar-equivalent doses. CONCLUSIONS: These data support the testing of abicipar as a treatment for retinal diseases characterized by neovascularization and vascular leak.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Rodrigues GA, Mason M, Christie LA, et al. Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability. Invest Ophthalmol Vis Sci. 2018. PMID: 30535424. doi:10.1167/iovs.18-25307

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。